We love to hear from our listeners. Send us a message.
Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few years ago, who was? Fast forward to 2023, and we see an ADC arena that drove nearly $100 billion in M&A, licensing, and partnership deals, and a Daiichi Sankyo that can rightfully lay claim to lighting that fire. In fact, it was our guest on this episode of the Business of Biotech, Ken Keller, Chairman of the Board, President, and CEO at Daiichi Sankyo, Inc. who made the bold move to jump headlong into oncology armed with ADCs that, at the time, weren't exactly the darling of biotech. On this episode, Ken shares the story of his climb from "carrying the bag" all the way to the Big Biotech C-Suite, how and why Daiichi Sankyo pivoted from its roots in cardiovascular therapeutics into Oncology and ADCs, his reflections on the antibody-drug conjugate market, and a whole lot more.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
